SHA
ECYT

Smith Hayes Advisers’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Smith Hayes Advisers’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$66K – 306
2014
Q2 		$66K Buy
+10,000
New +$113K 0.02% 283

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Smith Hayes Advisers's ECYT Position: Q3 2014 in Review

Smith Hayes Advisers sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2014, closing a stake of 10,000 shares — an estimated $66K sold.

Smith Hayes Advisers first reported a position in ECYT in Q2 2014 and held it in 1 quarter. The position peaked at $66K in Q2 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q3 2014.

  • Smith Hayes Advisers reported no remaining Endocyte, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Smith Hayes Advisers sold 10,000 Endocyte, Inc. Common Stock shares in Q3 2014, an estimated $66K.
  • Smith Hayes Advisers first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Smith Hayes Advisers's Endocyte, Inc. Common Stock position peaked at $66K in Q2 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2014.

Based on Smith Hayes Advisers's 13F filing for Q3 2014, filed 14 Nov 2014.